FDA Gives Approval for Skin Cancer Drug, Zolinza
Zolinza, the most recent skin cancer drug has today received approval from the U.S. Food and Drug Administration (FDA). Zolinza
(vorinostat) capsules is mainly recommended// for the treatment of cutaneous T-cell lymphoma (CTCL) type of skin cancer when the disease persists, worsens, or returns dur...
New Report Just Published: World Multiple Myeloma Therapeutics Market Report
Cancer Drug II-37
FDA Grants Orphan-Drug Designation to Melphalan II-38
Merck Commences Phase II-b and Phase III Clinical Trial of
Clavis Initiates Phase II Trial of Elacytarabine II-38
Gilead Sciences Commences GS 9219 Phase I Clinical Trial II-38
ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity
...Results from two investigational Phase I trials of zolinza
(vorinostat) in combination with bortezomib provid...atients had a partial or minimal response from the zolinza
and bortezomib combination treatment. Data from a...e the first to evaluate the safety and efficacy of zolinza
as part of a combination regimen in patients with ...